Breaking News

Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS

CAMBRIDGE, Mass.–(Small business WIRE)–Amylyx Pharmaceuticals, Inc. right now declared that the U.S. Food items and Drug Administration (Fda) has accepted for evaluation its New Drug Software (NDA) for AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO also known as ursodoxicoltaurine)) for the treatment of amyotrophic lateral sclerosis (ALS). The Fda has granted Priority Evaluate and assigned […]